



**INFORMATION
DISCLOSURE STATEMENT**

Address to:
Box Patent Application
Commissioner for Patents

Attorney Docket	STAN201
First Named Inventor	Gerald R. Crabtree et al.
Application Number	09/960,708
Filing Date	September 19, 2001
Group Art Unit	1635
Examiner Name	Unassigned
Title	Methods and Compositions for Modulating Angiogenesis

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants are filing this Disclosure Statement at the time of filing the application, no fee is required.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 12.21.01

By: 
Bret E. Field
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. STAN201		SERIAL NO. 09/960,708	
APPLICANT: Gerald R. Crabtree							
FILING DATE: Septmber 19, 2001						GROUP: 1635	

OIPE
 DEC 27 2001
 PATENT & TRADEMARK

U.S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date <small>If Appropriate</small>	
AA	6,096,515	08/01/00	Crabtree et al.				

FOREIGN PATENT DOCUMENTS							
Document Number	Date	Country	Class	Subclass	Translation		
AB	Wo 00/30671	06/02/00	PCT		Yes	No	

OTHER ART <small>(Including Author, Title, Date, Pertinent Pages, Etc.)</small>	
AC	Folkman et al "Angiogenesis" <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 16, Issue of June 5, pp. 10931-10934, 1992
AD	Clipstone et al. "Identification of calcinerurin as a key signaling enzyme in T-lymphocyte activation" <i>Nature</i> , Vol. 357, 25 June 1992, pps 695-697
AE	Flanagan et al, "Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A" <i>Nature</i> , Vol 352 29 August 1991 pps 803-807
AF	Emmel et al. "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation" <i>Science</i> , Vol 246, 22 December 1989 pps 1617-1620
AG	Shaw et al, "Identification of a Putative Regulator of Early T Cell Activation Genes" <i>Science</i> , Vol 241, 8 July 1988 pps, 202-205
AH	Durand et al. "A 275 Basepair fragment at the 5' end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the t cell antigen receptor" <i>J. Exp. Med The Rockefeller University Press</i> , Vol. 165, February 1987 pps 395-407
AI	Durand et al, "Characterization of Antigen Receptor Response Elements within the Interleukin-2 Enhancer", <i>Molecular and Cellular Biology</i> , April 1988, C.1715-1724

F:\DOCUMENT\STAN (Stanford)\201\Form PTO-1449.doc

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	